Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues

Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them one of the mainstays of treatment for Systemic lupus erythematosus (SLE). Although their use has allowed controlling the disease and reducing...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical medicine Vol. 9; no. 9; p. 2709
Main Authors Porta, Sabrina, Danza, Alvaro, Arias Saavedra, Maira, Carlomagno, Adriana, Goizueta, María Cecilia, Vivero, Florencia, Ruiz-Irastorza, Guillermo
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 21.08.2020
MDPI
Subjects
Clinical medicine
Gene expression
Infections
Kinases
Lupus
Patients
Protein synthesis
Remission (Medicine)
Review
Online AccessGet full text
ISSN2077-0383
2077-0383
DOI10.3390/jcm9092709

Cover

More Information
Summary:Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them one of the mainstays of treatment for Systemic lupus erythematosus (SLE). Although their use has allowed controlling the disease and reducing acute mortality in severe conditions, the implementation of a scheme based on high doses for long periods has inevitably been accompanied by an increase in adverse effects and infections, including long-term damage. The objective of this review is to answer some important questions that may arise from its use in daily clinical practice, and to propose a paradigm based on the use of methylprednisolone pulses followed by medium-low doses and a rapid decrease of prednisone.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm9092709